-
EMA’s regulatory science strategy open for public consultation
EMA’s regulatory science strategy open for public consultation
-
EMA’s regulatory science strategy open for public consultation
EMA’s regulatory science strategy open for public consultation
EMA’s draft 'Regulatory Science to 2025' strategy is a plan for advancing EMA's engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. The draft strategy is currently open for public consultation until the end of June 2019.
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2019
The PRAC starts a new review of Xeljanz and recommends the withdrawal of the marketing authorisations for fenspiride medicines. A monthly statistical overview of the PRAC activity is available now on our website.
-
Working together for safe medicines in the EU
Working together for safe medicines in the EU
-
Working together for safe medicines in the EU
Working together for safe medicines in the EU
EMA launches a social media campaign to highlight how the European medicines regulatory network keeps medicines safe and effective.
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
EMA and the European Commission provide additional information to help pharmaceutical companies prepare for the UK’s withdrawal from the EU.
